文献速递胰腺与胆道疾病消化内镜

内镜超声联合临床特征鉴别自身免疫性胰腺炎与胰腺导管腺癌:多中心队列研究

Endoscopic ultrasound and clinical features for differentiating autoimmune pancreatitis and pancreatic ductal adenocarcinoma: a multicenter cohort study.
PubMed 文献 · Gastrointest Endosc · 2026-07-24

该回顾性多中心队列纳入中国6中心2013年1月至2024年4月接受EUS的577例AIP或PDAC患者,随机1:1分为主要队列(n=289)和验证队列(n=288)。LASSO回归筛选临床和EUS特征后建立多变量逻辑回归模型,整合模型在主要队列AUC为0.994(95%CI 0.986-0.999),验证队列AUC为0.984(95%CI 0.972-0.994),优于单独临床或EUS模型。

要点

  • 整合EUS特征与临床血清学变量可更平衡地鉴别AIP与PDAC。
  • IgG4升高、CA19-9升高、血管受累和弥漫性低回声为前4位特征。
  • 整合模型验证队列敏感度93.5%、特异度97.8%,需前瞻性验证。

核心结论

  • 联合EUS特征与临床及血清学变量鉴别AIP与PDAC的诊断性能比单独任一方式更平衡。

研究设计与样本

  • 回顾性多中心队列研究,纳入中国6中心577例接受EUS并诊断为AIP或PDAC的患者,按1:1随机分为主要队列(n=289)和验证队列(n=288)。

主要发现

  • LASSO回归筛选出16个非零系数,取前4个非共线性特征(IgG4升高、CA19-9升高、血管受累、弥漫性低回声)建模。
  • 主要队列AUC为0.994(95%CI 0.986-0.999),准确率97.2%,敏感度96.7%,特异度97.8%。
  • 验证队列AUC为0.984(95%CI 0.972-0.994),准确率95.5%,敏感度93.5%,特异度97.8%。
  • 整合模型在验证队列敏感度方面比单独临床或EUS模型更平衡。

关键数值与推荐

  • LASSO回归采用5折交叉验证确定最优临床特征(n=5)和EUS特征(n=17)。
  • AIP患者较PDAC患者略年轻,IgG4升高更常见,超声特征更符合弥漫性胰腺实质病变。

临床怎么用

  • 在临床实践中,可结合EUS特征与临床血清学变量(如IgG4、CA19-9、血管受累、弥漫性低回声)综合评估以鉴别AIP与PDAC。

局限性

  • 回顾性设计,存在过拟合风险,且缺乏独立外部验证,常规临床实施前需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Differentiating autoimmune pancreatitis (AIP) from pancreatic ductal adenocarcinoma (PDAC) remains a diagnostic challenge. Although there is limited evidence that EUS is useful for diagnosing AIP, its full potential has yet to be leveraged in practice. This study aimed to develop an interpretable, accurate, and clinically applicable multimodal AIP diagnostic model by combining EUS features with clinical parameters. METHODS: This was a retrospective study of 577 patients attending 6 centers in China who underwent EUS and were diagnosed with AIP or PDAC between January 2013 and April 2024. AIP and PDAC cases were randomly divided 1:1 into primary (n = 289) and validation (n = 288) cohorts. LASSO regression with 5-fold cross-validation was used to determine the optimal clinical (n = 5) and EUS (n = 17) features discriminating AIP from PDAC. Multivariable logistic regression analysis was performed to develop a predictive model, which was assessed in the primary and validation cohorts using receiver operating characteristic area under curve (AUC) and calibration curves. Comparator models based on clinical and EUS features alone were also evaluated using the same framework. Logistic regression coefficients were scaled to develop a clinical nomogram. RESULTS: Most clinical and EUS features differed significantly between patients with AIP and PDAC. Patients with AIP were slightly younger, were much more likely to have elevated immunoglobulin G4 (IgG4), and their ultrasound features were more consistent with a diffuse pancreatic parenchymal pathology. LASSO regression identified 16 nonzero coefficients, from which the top 4 features with the largest, noncollinear coefficients (elevated IgG4, elevated CA19-9, vascular involvement, and diffuse hypoechogenicity) produced a highly discriminative and well-calibrated model for AIP, with an AUC of 0.994 (95% CI, 0.986-0.999; 97.2% accuracy, 96.7% sensitivity, 97.8% specificity) for the primary cohort and an AUC of 0.984 (95% CI, 0.972-0.994; 95.5% accuracy, 93.5% sensitivity, 97.8% specificity) for the validation cohort. The integrated model showed more balanced diagnostic performance than clinical-only or EUS-only models, particularly with respect to validation sensitivity. CONCLUSIONS: Combining EUS features with clinical and serological variables yields more balanced diagnostic performance for differentiating AIP from PDAC than either modality alone. Given the retrospective design, risk of overfitting, and lack of independent external validation, prospective validation is required before routine clinical implementation.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Zhang S, Yan Z, et al. Endoscopic ultrasound and clinical features for differentiating autoimmune pancreatitis and pancreatic ductal adenocarcinoma: a multicenter cohort study. Gastrointest Endosc. 2026. PMID: 42497978. doi:10.1016/j.gie.2026.07.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。